{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:35:03Z","timestamp":1791470103907,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.radonc.2023.109746","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T03:24:05Z","timestamp":1686885845000},"page":"109746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis"],"prefix":"10.1016","volume":"186","author":[{"given":"Thiraviyam","family":"Elumalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Portner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neethu","family":"Billy Graham Mariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchana","family":"Wickramasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajanee","family":"Bhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Sabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalram","family":"Thippu Jayaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109746_b0005","unstructured":"Prostate cancer statistics. Cancer Research UK 2015. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer (accessed November 7, 2022)."},{"key":"10.1016\/j.radonc.2023.109746_b0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2023.109746_b0015","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 2018;68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","DOI":"10.3322\/caac.21442"},{"key":"10.1016\/j.radonc.2023.109746_b0020","unstructured":"National Comprehensive Cancer Network. NCCN Prostate Cancer Guidelines Version 3.2022 2022."},{"key":"10.1016\/j.radonc.2023.109746_b0025","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109746_b0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2023.109746_b0035","doi-asserted-by":"crossref","first-page":"djv119","DOI":"10.1093\/jnci\/djv119","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","volume":"107","author":"Lin","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2023.109746_b0040","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","article-title":"Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis","volume":"73","author":"Seisen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2023.109746_b0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.prro.2012.11.011","article-title":"Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival","volume":"3","author":"Tward","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109746_b0050","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2014.01.008","article-title":"The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study","volume":"88","author":"Rusthoven","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109746_b0055","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109746_b0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00066-012-0169-1","article-title":"Toxicity and outcome of pelvic IMRT for node-positive prostate cancer","volume":"188","author":"M\u00fcller","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2023.109746_b0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2013.08.006","article-title":"Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome","volume":"109","author":"Fonteyne","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109746_b0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: Data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109746_b0075","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2018.04.023","article-title":"Definitive radiation therapy and survival in clinically node-positive prostate cancer","volume":"101","author":"Bryant","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109746_b0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clon.2019.01.004","article-title":"Moderately hypofractionated radiotherapy in node-positive prostate cancer","volume":"31","author":"Mallick","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109746_b0085","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1002\/cam4.2985","article-title":"Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer","volume":"9","author":"Tsuchida","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2023.109746_b0090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ijrobp.2022.07.011","article-title":"Common iliac node-positive prostate cancer treated with curative radiation therapy: N1 or M1a?","volume":"114","author":"Chopade","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109746_b0095","first-page":"cam4.5554","article-title":"Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis","author":"Nakamura","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2023.109746_b0100","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.109746_b0105","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109746_b0110","doi-asserted-by":"crossref","first-page":"pkac043","DOI":"10.1093\/jncics\/pkac043","article-title":"Docetaxel for nonmetastatic prostate cancer: Long-term survival outcomes in the STAMPEDE randomized controlled trial","volume":"6","author":"James","year":"2022","journal-title":"JNCI Cancer Spectrum"},{"key":"10.1016\/j.radonc.2023.109746_b0115","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109746_b0120","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109746_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.898774","article-title":"Risk factors for biochemical recurrence after PSMA-PET-guided definitive radiotherapy in patients with De Novo lymph node-positive prostate cancer","volume":"12","author":"Spohn","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.109746_b0130","doi-asserted-by":"crossref","first-page":"TPS199","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS199","article-title":"PEARLS: A multicenter phase II\/III trial of extended field radiotherapy for androgen-sensitive prostate cancer patients with PSMA-avid pelvic and para-aortic lymph nodes at presentation","volume":"40","author":"Murray","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.109746_b0135","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109746_b0140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:39Z","timestamp":1759123539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023002840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"alternative-id":["S0167814023002840"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109746","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109746"}}